Evidence map›Paper›PMID 33798507›Full record

ReviewChemico-biological interactions2021

Role of phytoconstituents in the management of COVID-19.

Amiya Das, Deepti Pandita, Gaurav Kumar Jain, Pallavi Agarwal, Ajmer Singh Grewal, Roop K Khar, Viney Lather

Open access · greenAbstract readReview
In one paragraph

Review in Chemico-biological interactions, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
9.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Review
  3. Lipophilic Substances of the Leaves and Inflorescences ofMolecules (Basel, Switzerland) · 2025
    Article
  4. Review
  5. Article
  6. Observational
  7. Current drug discovery technologies · 2024
    Article
  8. Article
  9. Phytomedicines explored underSouth African journal of botany : official journal of the South African Association of Botanists = Suid-Afrikaanse tydskrif vir plantkunde : amptelike tydskrif van die Suid-Afrikaanse Genootskap van Plantkundiges · 2022
    Review
  10. Review
  11. Review
  12. Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications.Phytomedicine : international journal of phytotherapy and phytopharmacology · 2022
    Article
  13. Natural products can be used in therapeutic management of COVID-19: Probable mechanistic insights.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022
    Review
  14. Article
  15. Metabolites of Pinang YakiF1000Research · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Amiya DasAmity Institute of Molecular Medicine & Stem Cell Research (AIMMSCR), Amity University Uttar Pradesh, Sector-125, Noida, 201313, India.
Deepti PanditaDepartment of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University, Pushp Vihar, New Delhi, 110017, India. Electronic address: deeptipandita@yahoo.co.uk.
Gaurav Kumar JainDepartment of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University, Pushp Vihar, New Delhi, 110017, India.
Pallavi AgarwalAmity Institute of Molecular Medicine & Stem Cell Research (AIMMSCR), Amity University Uttar Pradesh, Sector-125, Noida, 201313, India.
Ajmer Singh GrewalGuru Gobind Singh College of Pharmacy, Yamunanagar, Haryana, India.
Roop K KharBS Anangpuria Institute of Pharmacy, Faridabad, Haryana, India.
Viney LatherAmity Institute of Pharmacy, Amity University Uttar Pradesh, Sector-125, Noida, 201313, India. Electronic address: vinnylather@gmail.com.
Amity University · INDelhi Pharmaceutical Science and Research University · INGuru Gobind Singh Medical College and Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCOVID-19, a severe global pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has emerged as one of the most threatening transmissible disease. As a great threat to global public health, the development of treatment options has become vital, and a rush to find a cure has mobilized researchers globally from all areas. SCOPE AND APPROACH: This review focuses on deciphering the potential of different secondary metabolites from medicinal plants as therapeutic options either as inhibitors of therapeutic targets of SARS-CoV-2 or as blockers of viral particles entry through host cell receptors. The use of medicinal plants containing specific phytomoieties could be seen in providing a safer and long-term solution for the population with lesser side effects. Key Findings and Conclusions: Considering the high cost and time-consuming drug discovery process, therapeutic repositioning of existing drugs was explored as treatment option in COVID-19, however several molecules have been retracted as therapeutics either due to no positive outcomes or the severe side effects. These effects call for exploring the alternate treatment options which are therapeutically effective as well as safe. Keeping this in mind, phytopharmaceuticals derived from medicinal plants could be explored as important resources in the development of COVID-19 treatment, as their role in the past for treatment of viral diseases like HIV, MERS-CoV, and influenza has been well reported. Considering this fact, different phytoconstituents such as flavonoids, alkaloids, tannins and glycosides etc. Possessing antiviral properties against coronaviruses and possessing potential against SARS-CoV-2 have been reviewed in the present work.

Indexed as

COVID-19 Drug TreatmentAlkaloidsAnthraquinonesAntiviral AgentsFlavonoidsHumansOils, VolatilePhytochemicalsPlants, MedicinalSaponinsSecondary MetabolismAlkaloidsAnthraquinonesAntiviral AgentsFlavonoidsOils, VolatilePhytochemicalsSaponinsACE-2COVID-19COVID-19 main proteasenCoV-2019PhytoconstituentsTMPRSS2

Identifiers

PMID33798507
PMCPMC8008820
OpenAlexW3142323764

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.